РАЦИОНАЛЬНАЯ АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ У ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ ФОРМОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ ПРИ ПРОВЕДЕНИИ КАТЕТЕРНОЙ ИЗОЛЯЦИИ УСТЬЕВ ЛЕГОЧНЫХ ВЕН

С целью определения эффективности и безопасности катетерной изоляции устьев легочных вен у пациентов с пароксизмальной формой фибрилляции предсердий с учетом риска всех осложнений, в том числе тромбоэмболических и геморрагических, обследованы и прооперированы 243 пациента, 142 (58,44%) мужчины и 101 (41,56%) женщина в возрасте 25-79 лет (средний возраст - 56,09±10,14 года) с аритмическим анамнезом 4,48±2,6 года.

фибрилляция предсердий, радиочастотная катетерная аблация, легочные вены, тромбоэмболические осложнения, геморрагические осложнения, варфарин, ривароксабан, дабигатран, апиксабан

1. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the ESC. Developed with the special contribution of the EHRA of the ESC. Endorsed by the ESO // European Heart Journal doi: 10.1093/eurheartj/ehw210.

2. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО и ВНОА, 2012 // Российский кардиологический журнал 2013; 4(102), приложение 3: 6-7, 61-76.

3. Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation - a translational appraisal // Physiol Rev 2010.

4. Calkins H., Kuck K.H., Cappato R., et al. 2012 HRS/ EHRA/ECAS Expert Consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design // Europace2012; 14(4): 528-606.

5. Scherr D., Sharma K., Dalal D., et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation // J Cardiovasc Electrophysiol. Dec2009; 20(12): 1357-1363.

6. Wazni O.M., Rossilo A., Marrouch N.F. (2005) Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging // J Cardiovacs Electrophysiol 16(6): 576-581. doi: 10.1111/j.1540-8167.2005.40480.x

7. Karasoy D., Gislason G.H., Hansen J. et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding long-term follow-up in nationwide cohort of Denmark // Eur Heart J 2015; 36: 307.

8. Sticherling C., Marin F., Birnie D. et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS) // Europace (2015) 17, 1197-1214.

9. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation // Ann Intern Med 2007; 146: 857-867.

10. Клинические рекомендации по проведению электро-физиологических исследований, катетерной аблациии применению антиаритмических устройств ВНОА, 2013, 3-е издание. - Москва: МАКС Пресс, 2013: 7355.

11. McCready J.W., Nunn L., Lambiase P.D. et al. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is pre-procedural transoesophageal echocardiography mandatory? // Europace. 2010 Jul; 12(7): 927-32.

12. Cappato R., Ezekowitz M.D., Klein A.L. et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation // Eur Heart J. 2014; 35: 3346-3355.

13. Heidbuchel H., Verhamme P., Antigs A. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation // Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology 2015, 17(10): 1467-507.

14. Lip G.Y.H., Hammerstingl C., Marin F. et al. Left Atrial Thrombus Resolution in Atrial Fibrillation or Flutter: Results of a Prospective Study with Rivaroxaban (X-TRA) and a Retrospective Observational Registry Providing Baseline Data (CLOT-AF) // American Heart Journal, published online May 17th, 2016.

15. Bernhardt P. et al. Fate of Left Atrial Thrombi in Patients With Atrial Fibrillation Determined by Transesophageal Echocardiography and Cerebral Magnetic Resonance Imaging // Am J Cardiol 2004; 94: 801-804.

16. Gregory Y.H., Lip et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in non-valvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J 2015; 169: 464-471.e2.

17. Dillier R., Ammar S., Hessling G. et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures // Circ Arrrhythm Electrophysiol 2014; 7: 576-82.

18. Cappato R., Marchinski F.E., Hohnloser SH et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation // Eur Heart J 2015; 36: 1805-11.

19. Di Biase L., Burkhardt J.D., Santangeli P. et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management results from the role Coumadin in preventing thromboembolism in atrial fibrillaition (AF) patients undergoing catheter ablation (COMPARE) randomized trial // Circulation 2014; 129: 2638-44

20. Беликов Е.А., Давтян К.В., Ткачева О.Н. и соавт. Применение ривароксабана в периоперационном периоде катетерной изоляции устьев легочных вен у пациентов с пароксизмальной фибрилляцией предсердий // Кардиология 2015; 4(55): 36-40